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1. Introduction
Biomarker research represents an evolving area within
hepatology. The growing burden of global liver disease, the
absence of symptoms until late in the natural history of a
disease which may take decades to manifest, the presence
of an invasive reference test (liver biopsy) to assess disease
severity, and the lack of robust tools to assess the eﬃcacy of
therapeutic interventions are some of the key drivers for this
research.
The National Institute of Health defines a biomarker as
“A characteristic that is objectively measured and evaluated
as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention” [1]. Moreover, biomarkers can be classified
into hierarchical systems based on their ability to assess
natural history (type 0: prognosis), biological activity (type
1: response to therapy), and therapeutic eﬃcacy (type 2:
surrogate for clinical eﬃcacy) [2].
The spectrum of pathological injury that occurs in liver
disease including steatosis, necroinflammation, apoptosis,
and fibrosis enhances the pool of potential biomarkers.
Furthermore, advances in technology platforms have created
an exponential rise in the discovery of putative mediators
of pathophysiological injury. This has been countered by
the growing need to align surrogate markers of injury with
clinical consequences of injury in order to achieve diagnostic,
prognostic, and therapeutic eﬀectiveness. This timely special
edition comprises original articles and reviews in the subject
areas of biomarker discovery, biomarkers of liver injury, and
biomarkers to assess the consequences of liver injury.
2. Methods of Biomarker Discovery
Advances in instrumentation design have driven biomarker
discovery. The advent of modern biological mass spectro-
scopic techniques in the 1990s and the evolution of 2-
dimensional polyacrylamide gel electrophoresis (2D SDS
PAGE) from a highly specialist technique to one that could
be carried out in most laboratories around the world drove
the development of large-scale ‘omics biomarker discovery
projects. Advances in microlitre flow rate HPLC, that could
be coupled directly to mass spectrometers (nano-LC/MS),
and computing to analyse the data gave further impetus
to this work. It became possible to quantify and identify
many thousands of proteins from diseased and healthy tissue
in a single experiment. Biomarker discovery projects ([3]
metabonomics; [4] lipidomics; [5] proteomics; [6] SELDI
and transcriptomics) demonstrate the ability to identify
novel markers of liver disease. Proteomics, transcriptomics,
lipidomics, and metabonomics oﬀer the ability to discover
completely novel markers of disease and its progression.
This de novo approach to biomarker discovery leads to a
great challenge of marker validation. There may be little
or no obvious mechanistic connection between the putative
marker and disease, demonstrating that a link can be very
time and resource intensive.
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Mechanism-focussed biomarker discovery has also bene-
fited from advances in instrumental design and technology.
These projects are based on prior disease knowledge and
are much more limited in scope but, if successful, are
more likely to identify a disease-relevant marker. Standard
ELISA assays methodologies have been developed to use
valuable patient samples more eﬃciently by allowing many
analytes to be quantified simultaneously. In array or planar
assays, a series of primary antibodies are bound to a surface
in discrete spots, sample, and secondary antibody, and
detection reagents are passed over the array and the location
of the signal is determined using imaging technology. Bead-
based technologies rely on a mixture of antibody-labelled
beads which are then quantified using flow cytometers or
dedicated analysers. From 30 to 50 proteins can be analysed
per experiment using panels of antibodies that have been
optimised to minimise cross-reactivity. Miniaturisation of
liquid handling and high-density microplates, currently up
to 1536 samples per plate, reduces reagent and patient sample
usage when carrying out enzyme activity-based biomarker
discovery. A typical 96-well microplate will require 100 μL
reaction mix per well, the high density; 1536-well plates
require only 5 μL per well, a reduction of 20-fold in sample
consumption. Unfortunately, the additional costs that are
incurred to ensure accurate reagent dispensing and reaction
monitoring are not trivial. S. K. Hartwell, in this issue,
describes an alternative approach using flow injection to
minimise reagent consumption where sample numbers and
volumes may be limited. The use of commonly available
laboratory equipment aims to minimise costs and to open
up the technology to laboratories with limited resources.
3. Biomarkers of Liver Injury
The pathological processes of steatosis, necroinflammation,
oxidative stress, apoptosis, and fibrosis are common to
a number of diverse liver diseases. The ability to define
these individual entities is advantageous for determining
the mechanistic evidence of eﬃcacy, using biomarkers, for
proposed treatment strategies. A diﬃculty remains that the
pathological processes are often interdependent or cocorre-
lated, and thus, delineating biomarkers specific to one mode
of injury can be challenging. This is illustrated by the article
in this special edition by N. Mousa and coworkers describing
the association of alpha fetoprotein (AFP) and liver steatosis
in genotype 4 infection in chronic viral hepatitis. The authors
postulate that the elevation in AFP is secondary to increased
production from hepatic progenitor cells as a response to
regeneration following injury. In this study, steatosis was
also associated with the presence of necroinflammation
and fibrosis, and thus, it is not clear whether it is the
extent of liver injury or steatosis per se that leads to the
elevation in AFP. There exists a wider debate in the literature
on whether benign steatosis (in the absence of significant
steatohepatitis or fibrosis) has clinical significance. In viral
hepatitis, steatosis is most commonly seen in genotype 3
infection and improves following successful viral eradication
[7]. In long-term studies based on pathological features at
baseline biopsy, steatosis has not been shown to adversely
aﬀect outcome in nonalcoholic fatty liver disease [8, 9].
Natural history studies have shown that the presence and
stage of fibrosis at the index liver biopsy provide prognostic
information about the subsequent rate of fibrosis progres-
sion ([10–12] and the development of liver-related outcomes
[9, 13]). It is therefore no surprise that over the last decade
much of the focus has been to define novel biomarkers based
on the pathological presence of fibrosis. The success and
limitations of this strategy have been outlined elsewhere [14].
Defining surrogates of pathological entities other than liver
fibrosis is both necessary and advantageous for a number
of reasons. Liver fibrosis is essentially a generic wound-
healing response and final common pathway resulting from
a spectrum of hepatic insults. Moreover, particular charac-
teristics of the hepatic scar including the composition and
physical/biochemical attributes that limit remodelling and
angioarchitectural changes have hitherto made the delivery
of eﬀective antifibrotic therapy challenging. The ability to
intervene “upstream” in the injury process may yield a larger
repertoire of therapies with the allure of enhanced targeting
and superior drug profiles. Apoptosis in the liver may be one
such example. Whilst the engulfment of apoptotic bodies by
activated hepatic stellate cells (HSCs) may induce TGFβ and
collagen-α1 synthesis and promote fibrosis, paradoxically,
in preclinical models, resolution of fibrosis depends on the
removal of activated HSCs via apoptosis. Thus, the detailed
characterisation of apoptosis may provide critical insights
into both fibrogenesis and fibrinolysis. J. B. Chakraborty
and colleagues provide a comprehensive review in this
special edition of the mechanisms of apoptosis in the liver,
candidate apoptosis-related biomarkers, and the potential for
clinical translation (e.g., assessing treatment response and/or
monitoring the regression of fibrosis).
4. Biomarkers Assessing the Consequences
of Liver Injury
Following long-term liver injury, the evolution of liver
fibrosis to cirrhosis is associated with (1) architectural
disturbance; (2) angiogenesis and haemodynamic changes
(intra- and extrahepatic) resulting in portal hypertension;
(3) a propensity for carcinogenesis. In the event of the injury
not being removed, a proportion of aﬀected individuals will
have complications of liver failure, bleeding, hepatocellular
carcinoma, and death. The ability of biomarkers (at baseline
and/or changing over time) to predict these events directly
has the potential to improve prognosis and provide a mean-
ingful assessment of clinical eﬀectiveness (as opposed to
therapeutic eﬃcacy indicators such as reduction in fibrosis).
In hepatology, the limitations of liver biopsy and rather
restrictive pathological scoring systems have encouraged
the extrapolation of biomarkers (originally based upon
pathological end points) to hard clinical end points. There
are a number of studies demonstrating that noninvasive
biomarkers (including serum analytes and transient elastog-
raphy) measured at baseline predict liver-related outcomes
between 5 and 8 years [15–17].
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In this special edition, original research presented by N.
Palaniyappan and colleagues has investigated the prognostic
accuracy of validated scoring systems for detecting long-
term outcomes in alcoholic hepatitis. These scoring systems
showed a uniformly poor prognostic performance in detect-
ing mortality at one year (AUC ranges from 0.5 to 0.66),
in contrast to abstinence from alcohol within three to six
months of initial diagnosis which was associated with an
AUC of 0.83. This not only highlights the importance of
abstinence but also that dynamic measurement, in this case
of behaviour, can have a significant influence on prognosis in
the context of liver disease.
Portal hypertension underpins the major complications
of liver disease including variceal bleeding, ascites, and renal
failure. Both existing and emerging therapeutic strategies
in the context of established cirrhosis are directed towards
lowering portal hypertension. The gold standard for its
assessment remains the hepatic venous pressure gradient
(HVPG). Whilst a wealth of evidence supports its prognostic
value and utility in directing management [18, 19], it
remains an invasive test that is only available in specialist
centres. Thus, the search for robust biomarkers that oﬀer
a noninvasive alternative to HVPG is important if portal
hypertension is to be assessed in routine clinical practice. The
review by V. K. Snowdon and colleagues succinctly outlines
the pathophysiological basis of portal hypertension and, in
particular, uses examples of recent advances in endothelial
cell biology/fibrosis and angiogenesis research to support the
rationale for emerging biomarkers in this area.
Hepatocellular carcinoma (HCC) is the fifth leading
cause of death from cancer in men, the seventh leading
cause of death from cancer in women, and the fastest
rising cause of cancer mortality worldwide. The majority
of patients present at an advanced stage when treatment
options are very limited and, consequently, HCC carries a
dismal prognosis (overall median survival of 14 weeks, 1-
year survival of 13%). Current screening strategies that rely
on AFP and ultrasound are widely accepted but have only
modest diagnostic accuracy with sensitivity rates between
25% and 65% [20]. There is an urgent need to discover
and implement better diagnostic tools for this malignancy
that may permit earlier and more accurate detection and
the review by T. Behne and M. S. Copur outlines emerging
biomarkers that have potential clinical utility.
To provide stratified care for patients with liver disease,
we urgently need noninvasive tools that can eﬀectively phe-
notype patients based on their degree of liver injury, natural
history, and clinical outcomes. It is unthinkable that the
choice of intervention in an individual patient still remains,
in many circumstances, an empirical exercise involving “trial
and error.” Biomarker research and its dissemination should
aim to overcome these barriers to individualising care.
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